Researchers at Oregon State University have developed a technique for simultaneously treating lung cancer and a serious muscle-wasting condition that often accompanies it. The study, published in the ...

An Oregon veteran's 16-year fight with the VA over benefits for inclusion body myositis, or IBM, is part of a growing ...

Inclusion body myositis (IBM) is a slowly progressive muscle-wasting disease that typically starts with weakness in the hands and upper legs and often leads to difficulty swallowing. There is no cure, ...

Researchers at Oregon State University have developed a technique for simultaneously treating lung cancer and a serious muscle-wasting condition that often accompanies it.

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, will be presenting the results ...

Spinal muscular atrophy (SMA) is a rare, genetic condition that, across all types, affects ~1,600 people in the UK.1 It can cause muscle weakness which gets worse over time, causing movement, ...

In the battle of the obesity bulge, glucagon-like peptide-1 receptor agonist medications — aka GLP-1s such as Wegovy and Zepbound — have changed the game for some people who’ve struggled to lose ...

An international research team with the participation of researchers from the University Medical Center Göttingen (UMG), ...

The owner of the now-shuttered West Coast Game Park Safari pleaded guilty Monday morning to more than 40 charges of ...

Oral medicine subsidies for patients aged 25 or above began early this year but adults still lack public funding for ...

Sarepta Therapeutics (SRPT) stock and Roche (RHHBY) stock are in focus as Duchenne therapy Elevidys faces a new late-stage ...

The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' Ingrezza drug to treat movement disorders associated with Huntington's disease (HD), the ...